MARKET NEWS

CorMedix Announces FDA Acceptance for Filing & Priority Review of NDA
LSNE-León Receives Approval From AEMPS to Manufacture Biotechnology-Based Therapeutic Products
Novavax & Canada Reach Agreement in Principle to Acquire COVID-19 Vaccine
First Patient Dosed in AstraZeneca’s Phase 3 COVID-19 Vaccine Trial
Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line
Micron Biomedical Progresses With Clinical Evaluation of its Technology for Measles-Rubella Vaccination

  FEATURED EDITORIAL

  COMPANY PROFILE

Founded in 1897, BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to healthcare. BD’s drug delivery systems are designed to protect, package, and deliver drug therapies and to maximize healthcare worker and patient safety. Click here for more.

  EXCLUSIVE ONLINE CONTENT

SGS Enrolls First Patient Into Biophytis COVA Clinical Study, a COVID-19 Related Acute Respiratory Failure Treatment Clinical Trial

SGS Enrolls First Patient Into Biophytis COVA Clinical Study, a COVID-19 Related Acute Respiratory Failure Treatment Clinical Trial

SGS recently announce the enrollment of the first patient into an important new clinical trial designed to examine the safety, tolerability, and efficacy of….

Gilead Sciences & Jounce Therapeutics Announce Exclusive License Agreement

Gilead Sciences & Jounce Therapeutics Announce Exclusive License Agreement

Gilead Sciences, Inc. recently announced an agreement with Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively…

Avomeen & Daré Bioscience Form Strategic Partnership to Accelerate Novel Pipeline

Avomeen & Daré Bioscience Form Strategic Partnership to Accelerate Novel Pipeline

Avomeen and Daré Bioscience, Inc. recently announced the companies have signed an agreement under which Avomeen will provide….

Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial

Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial

Alimera Sciences, Inc. recently announced it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multi-center study designed to…

Chiasma Announces US Commercial Launch & Availability of the First & Only Oral Somatostatin Analog

Chiasma Announces US Commercial Launch & Availability of the First & Only Oral Somatostatin Analog

Chiasma, Inc. recently announced the commercial launch and availability of MYCAPSSA (octreotide) capsules in the US for patients with acromegaly. MYCAPSSA, the first and only….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 16 – Lyophilization Manufacturing
September 23 – Excipients